CMS Claims Too Much Authority Over Medicare Rx Prices – PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services incorrectly interprets the Medicare Modernization Act to allow "justification of aggregate price levels for groups of drugs," PhRMA asserts in comments on CMS' proposed Part D regs.
You may also be interested in...
Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information
Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.
Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information
Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.
Medicare Rx Course Is Clearer Following Bush Victory
President Bush's victory in the Nov. 2 election means that the Centers for Medicare & Medicaid Services will have a chance to create a stand-alone drug insurance program under Medicare